How and where to order Bimatoprost (Latisse, Lumigan, Careprost) ophthalmic solution 0.03% 3 ml online:
LATISSE (BIMATOPROST) OPHTHALMIC SOLUTION 0.03%: CLINICAL STUDIES (see "References")
Latisse solution was evaluated for its effect on overall eyelash prominence in a multicenter, double-masked, randomized, vehicle-controlled, parallel study including 278 adult patients for four months of treatment. The primary efficacy endpoint in this study was an increase in overall eyelash prominence as measured by at least a 1-grade increase on the 4-point Global Eyelash Assessment (GEA) scale, from baseline to the end of the treatment period (week 16). Latisse (Bimatoprost) ophthalmic solution) 0.03% was more effective than vehicle as measured by the GEA score, with statistically significant differences seen at 8-week, 12-week, and 16-week (primary endpoint) treatment durations.
In this study, patients were also evaluated for the effect of Latisse solution on the length, thickness and darkness of their eyelashes. Improvements from baseline in eyelash growth as measured by digital image analysis assessing eyelash length, fullness/thickness, and darkness were statistically significantly more pronounced in the bimatoprost group at weeks 8, 12, and 16.
After the 16-week treatment period, a 4-week post-treatment period followed during which the effects of bimatoprost started to return toward baseline. The effect on eyelash growth is expected to abate following longer term discontinuation.
Recent posts:
Latisse prescribing information
|